系统性硬化病RNP抗体的临床意义  

Clinical Significance of the RNP Antibody in Systemic Sclerosis Patients

作　　者：叶杨[1] 李敏[1] 石连杰[1] 赵臻怡[1] 钟雪[1] 陈清容[1] 谢一舟[1] 杨南萍[1] 

机构地区：[1]四川大学华西医院风湿免疫科,四川成都610041

出　　处：《华西医学》2009年第8期2070-2072,共3页West China Medical Journal

摘　　要：目的:分析并探讨RNP抗体在系统性硬化病中的临床意义。方法:收集自2004年以来在我院做过皮肤活检,并通过病理和临床确诊为系统性硬化病的62例住院患者。分为RNP+组(20例),SCL-70+组(20例),ENA-组(22例)。结果:RNP+组较其它两组关节痛、雷诺现象发生率明显升高(P<0·05),肌炎发生率亦有升高,指端病变发生率明显降低(P<0·05)。结论:通过对系统性硬化病患者体内部分典型抗体的研究,有利于临床医生判断不同抗体阳性的系统性硬化瘤患者病情的严重程度和预后。Objective：To analysis and explore clinical significance of the RNP antibody in systemic sclerosis.Methods： Twenty-two cases of systemic sclerosis proven by the skin biopsy pathology and clinical diagnosis were summarized in West China Hospital since 2004 and they were divided into RNP positive group （20 cases）, SCL-70 positive group （20 cases） and ENA negative group （22 cases）. Results： Compared with SCL-70 group and ENA negative group, RNP positive group had more unique clinical features, including the increasing incidence of arthralgia, Reynauds phenomenon （P〈0. 05） and myositis; on the contrary, including the decreasing incidence of tip lesion （P〈0. 05）. Conclusion： It is helpful for clinical doctors to determine the disease severity and prognosis from the different antibodies in patients with systemic sclerosis by the study of some typical antibodies existing in systemic sclerosis patients,

关 键 词：硬皮病 RNP抗体 ENA抗体 

分 类 号：R593.25[医药卫生—内科学]